১০% ইনস্ট্যান্ট ক্যাশব্যাক পুরো জানুয়ারি মাসজুড়ে বই ও পণ্যে বিকাশে মাত্র ৬০০৳+ পেমেন্টে সর্বোচ্চ ১০০৳ পর্যন্ত! পুরো ক্যাম্পেইনে ক্যাশব্যাক পাবেন ১৫০৳ পর্যন্ত!*
আরো দেখুন
১০% ইনস্ট্যান্ট ক্যাশব্যাক পুরো জানুয়ারি মাসজুড়ে বই ও পণ্যে বিকাশে মাত্র ৬০০৳+ পেমেন্টে সর্বোচ্চ ১০০৳ পর্যন্ত! পুরো ক্যাম্পেইনে ক্যাশব্যাক পাবেন ১৫০৳ পর্যন্ত!*
অনলাইন বাণিজ্য মেলায় আপনার পছন্দের পণ্যে ৭৫% পর্যন্ত ছাড়! বছরের শুরুতেই সেরা ডিল, রকমারি অনলাইন বাণিজ্য মেলা, ২০২৬
বইটি বিদেশি প্রকাশনী বা সাপ্লাইয়ারের নিকট থেকে সংগ্রহ করে আনতে আমাদের ৩০ থেকে ৪০ কর্মদিবস সময় লেগে যেতে পারে।
At the start of 2020, Moderna was a biotech unicorn with dim prospects. Yes, there was the promise of its disruptive innovation that could transform medicine by using something called messenger RNA, one of the body's building blocks of life, to combat disease. But its stock was under water. There were reports of a toxic work culture. And despite ten years of work, the company was still years away from delivering its first product. Investors were getting antsy, or worse, skeptical.
Then the pandemic hit, and Moderna, at first reluctantly, became a central player in a global drama—a David to Big Pharma's Goliaths—turning its technology toward breaking the global grip of the terrible disease. By year's end, with the virus raging, Moderna delivered one of the world's first Covid-19 vaccines, with a stunningly high rate of protection. The achievement gave the world a way out of a crippling pandemic while validating Moderna's technology, transforming the company into a global industry power. Biotech, and the venture capital community that fuels it, will never be the same.
Wall Street Journal reporter Peter Loftus, veteran reporter covering the pharmaceutical and biotech industries and part of a Pulitzer Prize–finalist team, brings the inside story of Moderna, from its humble start at a casual lunch through its heady startup days, into the heart of the pandemic and beyond. With deep access to all of the major players, Loftus weaves a tale of science and business that brings to life Moderna's monumental feat of creating a vaccine that beat back a deadly virus and changed the business of medicine forever.
The Messenger spans a decade and is full of heroic efforts by ordinary people, lucky breaks, and life-and-death decisions. It's the story of a revolutionary idea, the evolution of a cutting-edge American industry, and one of the great achievements of this century.
PETER LOFTUS is a reporter for the Wall Street Journal, covering the drug and medical-device industries and other health care topics. He was part of a Journal team that won second place in the business category of the 2020 Association of Health Care Journalists’ awards for coverage of the race for a Covid-19 vaccine. In 2016 he was part of a Journal team that was a finalist for the Pulitzer Prize in explanatory reporting for a series of articles about rising prescription drug prices. Before joining the Journal in 2013, he was a reporter for Dow Jones Newswires, covering the pharmaceutical and technology industries. Before that, he worked for community newspapers in suburban Philadelphia. He graduated from the University of Notre Dame with a bachelor’s degree in English and history. He lives outside Philadelphia with his wife and three children.